FinanceAsianet Newsable
ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data
in5points
Arrowhead Pharmaceuticals (ARWR) had its best day in nearly 8 months.
Chardan analyst Keay Nakae raised the price target on Arrowhead to $115 from $90.
The analyst maintains a Buy rating on Arrowhead shares.
The price target increase was driven by Plozasiran data.
Asianet Newsable
Center-right
Mixed factuality
Who owns this?
Asianet News Network
Rajeev Chandrasekhar / Jupiter Capital interests historically